Abstract
Purpose
Depletion of cellular nicotinamide adenine dinucleotide (NAD) by inhibition of its synthesis is a new pharmacological principle for cancer treatment currently in early phases of clinical development. We present new and previously published data on the safety and efficacy of these drugs based on early clinical trials.
Methods
A phase I clinical trial of CHS 828 in patients with advanced solid tumours was performed. Published clinical trials on NAD depleting drugs for cancer treatment were summarised for safety and efficacy.
Results
Seven patients with previously treated solid tumours received oral administration of CHS 828 in the dose range 20–80 mg once weekly for 3 weeks in 4 weeks cycles. Toxicity was dominated by gastrointestinal symptoms including nausea, vomiting, diarrhoea, constipation, subileus and gastric ulcer. One patient had thrombocytopenia grade 2. There were two cases each of grade 3–4 hyperuricemia and hypokalemia. Safety and efficacy of the NAD depleting drugs CHS 828 and FK866 have been reported from four phase I clinical trials, including a total of 97 patients with previously treated solid tumours. Outstanding toxicity reported was thrombocytopenia and various gastrointestinal symptoms. No objective tumour remission has been observed in the total of 104 patients treated in the above early trials.
Conclusions
Critical toxicity from NAD depleting cancer drugs to consider in future trials seems to be thrombocytopenia and various gastrointestinal symptoms. Efficacy of NAD depleting drugs when used alone is expected to be low.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chabner BA, Roberts TG Jr (2005) Chemotherapy and the war on cancer. Nat Rev Cancer 5:65–72
Nygren P, Larsson R (2003) Overview of the clinical efficacy of investigational anticancer drugs. J Internal Med 253:46–75
Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer’s achilles heel. Cancer Cell 13:472–482
Denko NC (2008) Hypoxia HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8:705–713
Khan JA, Forouhar F, Tao X, Tong L (2007) Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Exp Opin Ther Targets 11:695–705
Olesen UH, Knak Christensen M, Björkling F, Jäättelä M, Buhl Jensen P, Sehested M, Jensby Nielsen S (2008) Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 367:799–804
Mattevi A (2006) A close look at NAD biosynthesis. Nat Struct Mol Biol 13:563–564
Progrebniak A, Schemainda I, Azzam K, Pelka-Fischer R, Nüssler V, Hasmann M (2006) Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur J Med Res 11:313–321
Ekelund S, Larsson R, Nygren P (2002) Metabolic effects of the cytotoxic guanidino-containing drug CHS 828 in human lymphoma cells. Anticancer Res 22:2269–2274
Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, Tjornelund J, Dawson KM, Dupuis M, Duchosal MA (2009) The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematological malignancies. Blood 113:3276–3286
Khan JA, Tao X, Tong L (2006) Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol 13:582–588
Aleskog A, Bashir-Hassan S, Hovstadius P, Kristensen J, Höglund M, Tholander B, Binderup L, Larsson R, Jonsson E (2001) Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro. Anticancer Drugs 12:821–827
Jonsson E, Friberg L, Karlsson M, Hassan S, Nygren P, Kristensen J, Tholander B, Binderup L, Larsson R (2001) In vivo activity of CHS 828 on hollow-fiber cultures of primary human tumour cells from patients. Cancer Lett 26:193–200
Frost B-M, Lönnerholm G, Nygren P, Larsson R, Lindhagen E (2002) In vitro activity of the novel cytotoxic agent CHS 828 in childhood acute leukemia. Anticancer Drugs 13:735–742
Roulston A, Watson M, Bernier C, Chan H, Gratton M-O, Jang A, Koch E, Lavoie M, Paquette D, Mitchell M, Berger A, Belec L, Billot X, Shore G, Beauparlant P (2007) GMX1777: a novel inhibitor of NAD+ biosynthesis via inhibition of nicotinamide phosphoribosyl transferase. Proc AACR-NCI-EORTC conf Mol Targets Cancer Therapeutics San Francisco: A81
Watson M, Roulston A, Chan H, Goulet D, Bedard D, Turcotte E, Shore G, Viallet J, Beauparlant P (2008) Target identification permits rational development of the prodrug GMX1777 for the treatment of melanoma. Eur J Cancer Suppl 6:A470
Ekelund S, Persson I, Larsson R, Nygren P (2002) Interactions between the new cytotoxic drug CHS 828 and amiloride and mitomycin C in a human tumour cell line and tumour cells from patients. Chemotherapy 48:196–204
Hasmann M, Schemainda I (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 63:7436–7442
Hovstadius P, Larsson R, Jonsson E, Skov T, Kissmeyer AM, Krasilnikoff K, Bergh J, Karlsson MO, Lonnebo A, Ahlgren J (2002) A phase I study of CHS 828 in patients with solid tumour malignancy. Clin Cancer Res 8:2843–2850
Ravaud A, Cerny T, Terret C, Wanders J, Nguyen Bui B, Hess D, Droz J-P, Fumoleau P, Twelves C (2005) Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 41:702–707
Holen K, Saltz LB, Hollywood E, Burk K, Hanauske A-R (2008) The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 26:45–51
Pishvaian MJ, Marshall JL, Hwang JJ, Malik S, He AR, Deeken JF, Kelso CB, Cotarla I, Berger MS (2009) A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion. J Clin Oncol 27:A3581
Pishvaian MJ, Hwang JH, Malik S, He AR, Deeken JF, Kelso CB, Dorsch-Vogel K, Berger MS, Marshall JL (2008) A phase 1 trial of GMX1777: an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT). Eur J Cancer 6:A418
Acknowledgments
The support from clinical research nurse Marie Sjölund is gratefully acknowledged.
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
A. von Heideman and Å. Berglund contributed equally to this report.
Rights and permissions
About this article
Cite this article
von Heideman, A., Berglund, Å., Larsson, R. et al. Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother Pharmacol 65, 1165–1172 (2010). https://doi.org/10.1007/s00280-009-1125-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-009-1125-3